https://www.healthcaretribunefrance.com/article/914324401-abl-diagnostics-et-le-chru-nancy-premier-bilan-positif-pour-le-projet-predavir-apr-s-6-mois Healthcare Tribune France en PressRelease 2026-05-26T06:00:00+00:00 ABL Diagnostics et le CHRU Nancy : premier bilan positif pour le projet PREDAVIR après 6 mois https://www.healthcaretribunefrance.com/article/914846293-dr-daniel-pompa-joins-anthony-and-tereza-lolli-for-shealed-cannes-premiere Healthcare Tribune France en PressRelease 2026-05-25T04:06:47+00:00 Dr. Daniel Pompa Joins Anthony and TereZa Lolli for sHEALed Cannes Premiere https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24865794-anthony-tereza-lolli-alongsid-4096x2731.jpeg https://www.healthcaretribunefrance.com/article/914991134-ab-science-announces-that-its-stock-continues-to-be-covered-by-maxim-group-with-a-target-price-of-4-00-per-share Healthcare Tribune France en PressRelease 2026-05-25T16:06:43+00:00 AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share https://ml-eu.globenewswire.com/media/90d86a0e-7ea1-47ab-99d9-69985fa76ce0/small/logo-jpg.jpg https://www.healthcaretribunefrance.com/article/914991136-ab-science-annonce-que-le-titre-ab-science-continue-d-tre-couvert-par-maxim-group-avec-un-objectif-de-cours-de-4-00-par-action Healthcare Tribune France en PressRelease 2026-05-25T16:06:43+00:00 AB Science annonce que le titre AB Science continue d’être couvert par Maxim Group, avec un objectif de cours de 4,00 € par action https://ml-eu.globenewswire.com/media/90d86a0e-7ea1-47ab-99d9-69985fa76ce0/small/